Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 15,300 shares, a decrease of 64.0% from the August 15th total of 42,500 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 2,360,000 shares, the short-interest ratio is presently 0.0 days.

Salarius Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ SLRX traded up $0.02 during midday trading on Friday, reaching $1.56. 30,572 shares of the stock were exchanged, compared to its average volume of 872,332. The firm has a market cap of $931,320.00, a price-to-earnings ratio of -0.07 and a beta of 0.95. The firm has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $3.25. Salarius Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $7.60.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Friday, August 9th. The company reported ($2.37) EPS for the quarter, beating the consensus estimate of ($53.60) by $51.23. Research analysts expect that Salarius Pharmaceuticals will post -214.4 EPS for the current fiscal year.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.